Syneos Health Logo (WIPO, 06/11/2018)
WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark Syneos Health was filed as Figurative mark on 06/11/2018 at the World Intellectual Property Organization.
Logodesign (Wiener Klassifikation)
#Signs, notations, symbols #Letters presenting a special form of writing #Symbol of infinity #Series of letters in different dimensions
| Trademark form | Figurative mark |
| File reference | 1444337 |
| Countries | 
|
| Base trademark |
No. 87717521,
December 12, 2017
|
| Application date | June 11, 2018 |
| Expiration date | June 11, 2028 |
Trademark owner
1030 Sync Street
Morrisville NC 27560
US
Morrisville NC 27560
US
Trademark representatives
P.O. Box 64807
Chicago IL 60664-0807
US
goods and services
35
Strategic business consulting, marketing and advertising,
public relations communications strategy, information and
data collection, and data analytics, all in the
pharmaceutical, biotechnology and life sciences fields
(terms considered too vague by the International Bureau -
Rule 13 (2) (b) of the Common Regulations); sales promotion
services; market analysis and research services; personnel
recruitment and placement; recruitment services, namely,
advertising clinical trials, recruiting patients, and
placing patients for participation in clinical trials for
testing of pharmaceuticals and devices; consulting in sales
techniques and sales programs; sales volume tracking for
others, all in the pharmaceutical, biotechnology and life
sciences fields; business consulting in the field of
clinical trials, namely, clinical data and regulatory
submission management on behalf of medical, pharmaceutical
and biotechnology companies to assist them with clinical
research, clinical trials and applications for drug
approval; assisting pharmaceutical and biotechnology
companies with applications for drug approval
41
Education and training services in the field of
pharmaceutical sales; providing on-line, non-downloadable
newsletters and bulletins in the pharmaceutical,
biotechnology and life sciences fields; educational services
in the field of clinical trials, namely, webinars, videos,
articles, white papers, and podcasts
42
Medical, scientific and data analysis research services for
others, namely, conducting and analyzing clinical trials in
the pharmaceutical, biotechnology and life sciences fields;
pharmaceutical drug development services, namely, developing
clinical trial methodologies; consulting services in the
area of pharmaceutical clinical testing; extended clinical
research services for others, namely, computerized data
management of clinical trials, biostatistical analysis,
environmental consultancy, preclinical research and
development evaluation, repairing flawed clinical trials and
dossiers, strategic clinical research portfolio management,
and biosurveillance monitoring; providing life science and
scientific research information to physicians and other
health care professionals, patients, and medical,
pharmaceutical and biotechnology companies; provide
regulatory compliant technical writing services in the field
of medical research and clinical studies; consulting
services in the field of contract clinical research and
contract product development; Internet development, design
and consulting services for others, namely, creating
websites featuring blogs about medical and pharmaceutical
information related to chronic illnesses and disease,
creating an online community for patients and caregivers to
communicate about healthcare, and design and development of
interactive software for use in the communication and
dissemination of medical and pharmaceutical information
44
Providing medical information to physicians, other health
care professionals and for medical patients (terms
considered too vague by the International Bureau - Rule 13
(2) (b) of the Common Regulations); promoting health
information through direct-to-patient communications to
promote patient adherence (terms considered too vague by the
International Bureau - Rule 13 (2) (b) of the Common
Regulations)
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| February 5, 2020 | 2020/7 Gaz | ID | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| November 15, 2019 | 2019/51 Gaz | US | RAW: Partial Ceasing Effect |
| October 22, 2019 | 2019/45 Gaz | ID | Rejection |
| June 11, 2018 | 2018/52 Gaz | US | Registration |
ID: 141444337